PF-Atlas › Clinical Trials › NCT06764862

Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis

HSK44459 dose 1 · Phase 2

Registry ID
NCT06764862
Phase
Phase 2
Status
Completed
Drug / intervention
HSK44459 dose 1
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Start
2025-01-17
Enrollment
186
Locations
1

About this trial

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

View NCT06764862 on ClinicalTrials.gov →

Explore related

All HSK44459 dose 1 trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT06764862 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.